In this study, we find a subject with a deficiency of IL-1 receptor antagonist (DIRA) -like syndrome who also has symptoms similar to that of psoriasis. Within 24 hours of intravenous infusion with autologous SB cells®, the subject's IL-1 RA expression is shown to increase drastically, during which the subject experiences relief from his psoriasis-like symptoms.The subject was diagnosed with psoriasis as a young adult; however, no treatment has offered relief for the psoriatic plaques located along his forearms and back. Currently his diagnosis is classified as psoriasis and his management of the disease is minimal. Throughout the course of SB cell® treatments, we used ELISA to monitor a panel of cytokines, it was here we noticed the subject's deficient IL-1RA expression without treatment, his expression levels were near 0 pg/ml. 24 Hours after treatment, measurements of his expression levels were increased several thousand fold. This case presents the possibility that SB cells can act as a treatment for psoriasis due to IL-1 RA deficiency.

et al. Activation of PPARγ by SB cells® treatment for type 2 diabetes patients: a case study. Stem Cells Regen Med. 2017; 1(2) 003: 1-4. ABSTRACTManagement of blood glucose levels is vital for the health and well-being of those with type 2 diabetes mellitus. Current research has identified novel targets for regulating glucose and fat metabolism, with peroxisome proliferatoractivated receptors (PPAR) emerging as a candidate in treating type 2 diabetes. Diabetes mellitus medications may target the PPAR pathway, and the class of thiazolidinediones is a popular treatment that functions as PPARγ agonists. While this treatment is an established method for lowering blood glucose through increasing insulin sensitivity, patients may experience serious adverse effects such as hepatotoxicity and heart failure. Therefore, there is a need for safe and effective type 2 diabetes therapies. Stem cell research regarding diabetes mellitus has provided promising therapies for improving insulin sensitivity and normalizing blood glucose. The objective of this study is to examine the effects of the StemBios stem cell therapy on maintaining healthy glucose levels through the PPARγ pathway in type 2 diabetes patients. In this study, we tracked PPARγ levels before and after intravenous SB cells® (StemBios cell) infusion. The treatment led to an increase in PPARγ levels and stabilized blood glucose levels after the treatment, suggesting that the SB cells® treatment offers a therapeutic benefit for those with type 2 diabetes.

Although several bupivacaine-based long-acting local analgesics have been approved over the past decade or so, post-operative analgesia with minimal opioid use remains elusive. One reason for this may be because the pharmacokinetics (PK) from these formulations are inconsistent across multiple surgical models, leading to reluctance to use them in any surgical model where the PK curve has not already been demonstrated for fear of Local Anesthetic Systemic Toxicity (LAST) and concerns regarding inconsistent efficacy. Ropivacaine, widely considered to be safer than bupivacaine, has been developed as a novel extendedrelease formulation (CPL-01). As there is publicly available data demonstrating the PK of liposomal bupivacaine (LB) in several of the same surgical models as CPL-01, we compared the PK of ropivacaine from CPL-01 to that of bupivacaine from LB to better understand the consistency of their systemic exposure.Approach: Data on LB's PK was used to construct a dose-normalized curve across three surgical models after a 200 mg dose. These were then graphed alongside data from CPL-01 trials in abdominoplasty, herniorrhaphy, and bunionectomy, each of which had a 200 mg dose. The curves were then compared, focusing on the consistency of the shape of the curve, the mean Cmax, and the median Tmax. Results:The shape of the systemic local anesthetic curve was consistent after administration of CPL-01 across multiple surgical models but was not consistent after administration of LB (see Figure 1). The dose-normalized Cmax values were at least 4-fold lower than the accepted threshold for LAST concentration of 2,000 ng/mL (bupivacaine) or 2,200 ng/mL (ropivacaine) for all models, with little variance for either product, 268-352 ng/mL in LB and 284-455 ng/mL in CPL-01. However, when comparing median Tmax values across all three surgical models, CPL-01 showed a consistent Tmax of 8-12 h, while the Tmax for LB varied from 2-36 h.Conclusions: Consistent median Tmax values across surgical models with CPL-01 indicates a more predictable release of ropivacaine over time across multiple surgical models that is not present with LB. Mean peak plasma concentration levels for both CPL-01 and LB were well below the known toxicity levels. When approved, the predictability and consistency of the PK parameters of systemic ropivacaine from CPL-01 may provide physicians with more assurance in using extended-release anesthetics, with greater confidence of more consistent efficacy and less fear of inadvertently contributing to LAST.

Aims: Dementia is characterized by cognitive decline and memory loss, as well as impairment in short-term memory, long-term memory, and judgement. The cognitive deficits associated with dementia can interfere significantly with their social relationships and activities, as well as their occupational functioning. We believe that our SB cell® therapy may be the next step in treating non-Alzheimer's dementia. Presentation of Case:We describe four patients who have been diagnosed with non-Alzheimer's dementia and have experienced significant improvements in their memory, mood, cognitive functioning, and ability to do daily tasks after receiving our SB cells® treatment.Discussion: Patients receiving our stem cell therapy showed a significant decrease in CD10 expression, a marker for NEP. It suggested that there may be a beneficial effect of pharmaceutical inhibition of cerebral NEP on learning and memory due to the accumulation of peptides other than Aβ degradable by NEP. Conclusion:Our study may validate the existence of peptides targeted by NEP that may improve learning and provide a promising avenue to the treatment of non-Alzheimer's dementia. We hoped to continue investigating new patient cases to determine the potential CD10 has as a genetic marker of dementia.

Inflammantory back pain is a common symptom in Ankylosing spondylitis patients [1]. Since there is no cure for the disease, current treatment focuses on lower the symptoms and preventing progression of the disease [2]. Many laboratories had tried to use stem cell to teat Ankylosing spondylitis related symptoms and receive positive response from patients. Here we used SB cells ® to treat Ankylosing spondylitis patients. Not only patients showed lower pain symptom, but also patients did not report any side effect from the treatment. Here we used the SB cells ® which purified from patients' own body in their stem cell treatment. With our initial success, we are planning to perform SB cells ® treatment on a larger scale of Ankylosing spondylitis patients in the hope of obtaining larger data volume.